他克莫司治疗皮肌炎/多肌炎患者的疗效和安全性：一项荟萃分析与系统评价
The efficacy and safety of tacrolimus in patients with dermatomyositis/polymyositis: A meta-analysis and systematic review.
作者信息
Liao Jiafen, Peng Xiaofei, Liu Jiayi, Xie Xi, Wang Jia
机构信息
Department of Rheumatology and Immunology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Xiangya School of Medicine, Central South University, Changsha, Hunan 410011, China.
出版信息
Eur J Intern Med. 2023 Apr;110:35-40. doi: 10.1016/j.ejim.2023.01.018. Epub 2023 Jan 30.
OBJECTIVE
To evaluate the efficacy and safety of tacrolimus for dermatomyositis (DM) and polymyositis (PM) treatment.
METHODS
We searched the Embase, PubMed, the Cochrane Central Register of Controlled Trials, and China National Knowledge Infrastructure were used as searching tools from inception up to October 2022. Two authors independently selected studies. The available studies were comprehensively reviewed and investigated.
RESULTS
A total of 9 studies, including 350 patients, were analysed. Pooled results showed a higher overall survival rate in tacrolimus therapy group. Creatine kinase (CK) levels and forced vital capacity (FVC) showed significant improvement after tacrolimus therapy. The incidence of adverse events including infection and renal dysfunction showed no significant differences between the tacrolimus therapy group and conventional therapy group.
CONCLUSION
The results of this meta-analysis indicated that GC therapy in combination with tacrolimus therapy could help improving overall survival rate, pulmonary function and had similar safety outcomes compared to conventional therapy in DM and PM patients.
目的
评估他克莫司治疗皮肌炎（DM）和多发性肌炎（PM）的疗效和安全性。
方法
我们使用Embase、PubMed、Cochrane对照试验中央注册库和中国知网作为检索工具，检索时间从数据库建立至2022年10月。由两位作者独立选择研究。对纳入的研究进行全面的回顾和分析。
结果
共分析了9项研究，包括350例患者。汇总结果显示他克莫司治疗组的总生存率更高。他克莫司治疗后肌酸激酶（CK）水平和用力肺活量（FVC）有显著改善。他克莫司治疗组和传统治疗组之间包括感染和肾功能不全在内的不良事件发生率无显著差异。
结论
该荟萃分析结果表明，糖皮质激素（GC）联合他克莫司治疗可提高DM和PM患者的总生存率，改善肺功能，且安全性与传统治疗相似。
Zotero 插件